Journal
ALZHEIMERS & DEMENTIA
Volume 10, Issue 4, Pages 477-484Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2013.06.003
Keywords
Cerebrospinal fluid; Plasma; Serum; Autopsy; Neurodegeneration; Alzheimer's Disease; Dementia; Genetics; Parkinson's Disease; Frontotemporal lobar degeneration
Categories
Funding
- National Institutes of Health [AG39510, AG033101, AG17586, AG10124, NS053488, NS44266, AG15116]
- Wyncote Foundation
- Koller Family Foundation
- Fundacion Alfonso Martin Escudero
Ask authors/readers for more resources
Neurodegenerative diseases (NDs) are defined by the accumulation of abnormal protein deposits in the central nervous system (CNS), and only neuropathological examination enables a definitive diagnosis. Brain banks and their associated scientific programs have shaped the actual knowledge of NDs, identifying and characterizing the CNS deposits that define new diseases, formulating staging schemes, and establishing correlations between neuropathological changes and clinical features. However, brain banks have evolved to accommodate the banking of biofluids as well as DNA and RNA samples. Moreover, the value of biobanks is greatly enhanced if they link all the multidimensional clinical and laboratory information of each case, which is accomplished, optimally, using systematic and standardized operating procedures, and in the framework of multidisciplinary teams with the support of a flexible and user-friendly database system that facilitates the sharing of information of all the teams in the network. We describe a biobanking system that is a platform for discovery research at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. (C) 2014 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available